Show Notes
In this episode of Bladder Cancer Matters, host and survivor Rick Bangs sits down with Dr. Mark Schoenberg—renowned urologist and Chief Medical Officer at UroGen® Pharma—for a wide-ranging conversation about the evolution of bladder cancer research, treatment, and patient advocacy. Dr. Schoenberg shares the story behind BCAN's founding, the early challenges of raising awareness, and the innovations that are reshaping care today, including the development of non-surgical therapies like ZUSDURI™ (mitomycin) for intravesical solution, a prescription medicine used to treat adults with a type of cancer of the lining of the bladder called low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) after you have previously received bladder surgery to remove the tumor and it did not work or is no longer working. From his decades of patient-centered work to his role in pioneering new approaches with UroGen, Dr. Schoenberg offers insights into where the field has been and the promising future ahead. Tune in to hear a fascinating mix of history, science, and hope for patients and families impacted by bladder cancer. Please see the link to the full Prescribing Information on the podcast web page or available at www.zusduri.com. ZUSDURI Prescribing Information ZUSDURI Patient Information Holzbeierlein J, Bixler BR, Buckley DI, et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline: 2024 amendment. J Urol. 2024;10.1097/JU.0000000000003846. ZUSDURI (mitomycin) for intravesical solution is a prescription medicine used to treat adults with a type of cancer of the lining of the bladder called low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC) after you have previously received bladder surgery to remove tumor and it did not work or is no longer working. ZUSDURI™ Important Safety Information You should not receive ZUSDURI™ if you have a hole or tear (perforation) of your bladder or if you have had an allergic reaction to mitomycin or to any of the ingredients in ZUSDURI™. Before receiving ZUSDURI™, tell your healthcare provider about all of your medical conditions, including if you: have kidney problems are pregnant or plan to become pregnant. ZUSDURI™ can harm your unborn baby. You should not become pregnant during treatment with ZUSDURI™. Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with ZUSDURI™. Females who are able to become pregnant: You should use effective birth control (contraception) during treatment with ZUSDURI™ and for 6 months after the last dose. Males being treated with ZUSDURI™: You should use effective birth control (contraception) during treatment with ZUSDURI™ and for 3 months after the last dose. are breastfeeding or plan to breastfeed. It is not known if ZUSDURI™ passes into your breast milk. Do not breastfeed during treatment with ZUSDURI™ and for 1 week after the last dose. How will I receive ZUSDURI™? You will receive your ZUSDURI™ dose from your healthcare provider 1 time a week for 6 weeks into your bladder through a tube called a urinary catheter. It is important that you receive all 6 doses of ZUSDURI™ according to your healthcare provider's instructions. If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. During treatment with ZUSDURI™, your healthcare provider may tell you to take additional medicines or change how you take your current medicines. After receiving ZUSDURI™: ZUSDURI™ may cause your urine color to change to a violet to blue color. Avoid contact between your skin and urine for at least 24 hours. To urinate, males and females should sit on a toilet and flush the toilet several times after you use it. After going to the bathroom, wash your hands, your inner thighs, and genital area well with soap and water. Clothing that comes in contact with urine should be washed right away and washed
More from Bladder Cancer Matters
Can patients with muscle-invasive bladder cancer safely keep their bladders after successful treatment? And does having "no evidence of disease" really mean the cancer is gone? In this episode of Bladder Cancer Matters, host and bladder cancer survivor Rick Bangs welcomes back renowned bladder cancer expert Dr. Ashish Kamat of MD Anderson Cancer Center to explore one of the most important decisions patients may face: bladder removal or bladder preservation. Dr. Kamat explains how newer treatments are improving survival, what doctors can—and cannot—determine about whether cancer remains and the potential risks and benefits of preserving the bladder. He also discusses why ongoing monitoring is essential and what patients should ask their medical teams before making treatment decisions. If you or someone you love is facing bladder cancer treatment, this conversation offers valuable insights to help you understand your options and make informed decisions.
Bladder cancer treatment can change much more than a person's physical health — it can profoundly affect sexuality, intimacy, body image and relationships. In this candid and informative episode of Bladder Cancer Matters, host and bladder cancer survivor Rick Bangs talks with Mary Dunn, a certified adult nurse practitioner about a topic patients and partners may find difficult to discuss: sex after bladder cancer. Mary explains how bladder cancer and its treatments can affect sexual health for both men and women, offers practical strategies for managing common challenges and reviews treatment options that can help. Just as importantly, she explores intimacy beyond sex and encourages patients to make sexual health part of the conversation with their healthcare teams. Listener discretion advised: This episode contains explicit language and frank discussions of sexual health, sexual function and anatomy that may not be appropriate for all listeners.
In this eye-opening episode of Bladder Cancer Matters, brought to you by the Bladder Cancer Advocacy Network, host Rick Bangs sits down with Todd Davey of Ferring Pharmaceuticals to pull back the curtain on something most patients never hear about: market access. What actually happens between a breakthrough therapy and the moment a patient can affordably receive it? Todd walks listeners through the strategy, value demonstration, and launch planning that determine whether innovative bladder cancer treatments—like ADSTILADRIN®—are covered by insurance and accessible without crushing out-of-pocket costs. It's a candid, behind-the-scenes look at how science, economics, and patient advocacy intersect—and why getting this right can mean fewer barriers, less financial stress, and more options for families facing bladder cancer. If you've ever wondered how new treatments move from the lab to real life, this episode will give you clarity—and a new appreciation for the complex work that helps turn innovation into access.
For women facing radical cystectomy, removing the bladder doesn't always have to mean removing reproductive organs as well. In this episode of Bladder Cancer Matters, host Rick Bangs talks with Cleveland Clinic urologic oncologist Dr. Rebecca Campbell about organ-sparing radical cystectomy and how, for carefully selected patients, surgeons may be able to preserve the vagina, uterus and ovaries while still prioritizing effective cancer treatment. Dr. Campbell explains who may be a candidate, how organ sparing can help protect sexual function, hormonal health, continence and overall quality of life and why women should feel empowered to ask their surgeon about their options—or seek a second opinion if those options aren't discussed. It's an important conversation about looking beyond bladder removal to the life a patient wants to live after treatment.
In this fascinating episode of Bladder Cancer Matters, host Rick Bangs sits down with renowned bladder cancer expert Dr. Robert Svatek to discuss how the field has been transformed over the past 15 years—and where it's headed next. Dr. Svatek reflects on his journey from academic surgeon and researcher to Vice President of Clinical Development at CG Oncology, sharing behind-the-scenes insights into clinical trials, emerging immunotherapies and the collaborative effort required to bring promising new treatments from the laboratory to patients. Whether you're a patient, caregiver, advocate or healthcare professional, this conversation offers an inspiring look at the remarkable progress being made in bladder cancer research while acknowledging the challenges that remain. You'll also hear how patient participation in clinical trials is driving innovation and why experts are more optimistic than ever about the future of bladder cancer care.